other material
confidence high
sentiment positive
materiality 0.70
Veru's enobosarm Phase 2b meets primary endpoint; 71% less lean mass loss with GLP-1
VERU INC.
- Phase 2b QUALITY study met primary endpoint: 71% relative reduction in lean mass loss with enobosarm + semaglutide vs placebo (p=0.002).
- Enobosarm 3mg dose resulted in >99% mean relative reduction in lean mass loss (p<0.001); enobosarm 6mg not more effective.
- Enobosarm + semaglutide shifted weight loss composition to fat: 90.6% fat loss vs 68% with placebo (p=0.014 for fat mass loss with 6mg).
- Physical function improved: 54.4% relative reduction in proportion with ≥10% decline in stair climb power (p=0.0049) for all enobosarm.
- Upcoming catalysts: unblinded safety data and Phase 2b extension topline data expected in Q2 2025; End of Phase 2 FDA meeting planned for Q3 2025.